Biote (BTMD) Common Equity (2020 - 2026)

Biote's Common Equity history runs 7 years deep, the most recent figure standing at -$56.1 million for Q1 2026.

• In Q1 2026, Common Equity rose 33.88% year-over-year to -$56.1 million; the TTM figure through Mar 2026 stood at -$56.1 million (up 33.88% YoY), while the FY2025 annual figure was -$50.4 million, up 50.69% from the prior year.
• Common Equity for Q1 2026 stood at -$56.1 million, down from -$50.4 million in the prior quarter.
• The five-year high for Common Equity was $10.7 million in Q1 2022, with the low at -$141.5 million in Q2 2024.
• The 5-year median for Common Equity is -$70.8 million (2022), against an average of -$69.7 million.
• Peak annual rise in Common Equity reached 201.52% in 2022, while the deepest fall reached 5136.29% in 2022.
• Biote's Common Equity stood at -$58.3 million in 2022, then soared by 37.29% to -$36.5 million in 2023, then sank by 179.65% to -$102.2 million in 2024, then surged by 50.69% to -$50.4 million in 2025, then declined by 11.3% to -$56.1 million in 2026.
• Business Quant data shows BTMD's Common Equity at -$56.1 million in Q1 2026, -$50.4 million in Q4 2025, and -$65.5 million in Q3 2025.